Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation Expense EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Outstanding Shares Outstanding

Ratios

Vanda Pharmaceuticals (VNDA) Shares Issued (2016 - 2022)

Vanda Pharmaceuticals' Shares Issued history spans 12 years, with the latest figure at $634000.0 for Q4 2022.

On a quarterly basis, Shares Issued fell 39.1% to $634000.0 in Q4 2022 year-over-year; TTM through Dec 2023 was $609000.0, a 17.03% decrease, with the full-year FY2022 number at $734000.0, down 79.32% from a year prior.
Shares Issued hit $634000.0 in Q4 2022 for Vanda Pharmaceuticals, up from -$25000.0 in the prior quarter.
Over the last five years, Shares Issued for VNDA hit a ceiling of $100.9 million in Q1 2018 and a floor of -$95.4 million in Q3 2018.
Historically, Shares Issued has averaged $6.2 million across 5 years, with a median of $510000.0 in 2019.
Biggest five-year swings in Shares Issued: plummeted 2066.52% in 2018 and later surged 11470.0% in 2019.
Tracing VNDA's Shares Issued over 5 years: stood at $95.4 million in 2018, then tumbled by 97.69% to $2.2 million in 2019, then tumbled by 34.82% to $1.4 million in 2020, then fell by 27.41% to $1.0 million in 2021, then crashed by 39.1% to $634000.0 in 2022.
Business Quant data shows Shares Issued for VNDA at $634000.0 in Q4 2022, -$25000.0 in Q3 2022, and $125000.0 in Q2 2022.